Login Register Cart 0
Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Investigating Neuroprotective Potential of Berberine, Levetiracetam and their Combination in the Management of Alzheimer’s Disease Utilizing Drug Repurposing Strategy

Author(s): Anuradha Singh, Suneela Dhaneshwar* and Avijit Mazumder

Volume 18, Issue 2, 2023

Published on: 10 November, 2021

Page: [182 - 190] Pages: 9

DOI: 10.2174/2772432816666210910104306

Price: $65

Abstract

Aim: The aim of the present work was to evaluate the neuroprotective potential of berberine, levetiracetam and their combination in lead acetate-induced neurotoxicity by applying a drug repositioning approach.

Background: Alzheimer's disease (AD) is a neurodegenerative disease characterized by impairment of memory, disturbances in reasoning, planning, language and perception. Currently, there are only four drugs approved by US-FDA for AD; therefore, there is an extensive need for new drug development. The drug repositioning approach refers to the development of new uses for existing or abandoned pharmaceuticals. Several studies support the neuroprotective abilities of anti-oxidants resulting in neuronal protection against neurotoxins, suppression of oxidative stress and promotion of memory, learning and cognitive functions. Many natural polyphenols are being investigated as a potential therapeutic option for AD. Levetiracetam (LEV), a second-generation antiepileptic drug, is a new molecule that is clearly differentiated from conventional antiepileptic drugs by its pharmacologic properties. LEV also has been previously demonstrated to protect against oxidative stress-induced neurotoxicity in several models of seizures. Berberine (BBR) is an anti-inflammatory and anti-oxidant phytoconstituent.

Objective: To study the therapeutic effect of berberine, levetiracetam and their physical mixture in lead acetate-induced neurotoxicity in Swiss albino mice for probable application in the management of Alzheimer's disease.

Methods: Neurotoxicity was induced in Swiss albino mice by lead acetate. Behavioural parameters, such as transfer latency time and percentage alternation, were studied using Morris water maze (MWM), Elevated plus-maze test (EPM) and Y-maze for the assessment of improvement in learning and memory. Concentrations of acetylcholinesterase, MDA and GSH in the brain were also estimated. Brain samples were subjected to histopathological studies.

Results: Results revealed that the combination of BBR and LEV exhibited a significant neuroprotective effect by decreasing escape latency time and increasing time spent in the target quadrant in MWM. The combination also decreases transfer latency time in EPM and acetylcholinesterase levels in the brain as compared to standard donepezil. Reduced neuronal damage was also confirmed by the histopathological report.

Conclusion: Leveteracitam, berberin and their combination resulted in the significant conservation of various behavioural, biochemical, enzymatic and anti-oxidant parameters that were evaluated. The neuroprotective effect of plain leveteracitam and berberin was significantly better than their combination. The anticipated synergism or additive effect was not observed with the combination of leveteracitam and berberin in lead acetate–induced neurotoxicity.

Keywords: Oxidative stress, anti-inflammatory, drug repositioning, anti-oxidant, neurodegenerative disease, phytophenols.

« Previous Next »
Graphical Abstract

[1]
Frank L, Lloyd A, Flynn JA, et al. Impact of cognitive impairment on mild dementia patients and mild cognitive impairment patients and their informants. Int Psychogeriatr 2006; 18(1): 151-62.
[http://dx.doi.org/10.1017/S1041610205002450] [PMID: 16403246]
[2]
Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer’s disease: Phenomenology and treatment. J Clin Psychiatry 1987; 48 (Suppl.): 9-15.
[PMID: 3553166]
[3]
Millington C, Sonego S, Karunaweera N, et al. Chronic neuroinflammation in Alzheimer’s disease: New perspectives on animal models and promising candidate drugs. BioMed Res Int 2014; 2014: 309129.
[http://dx.doi.org/10.1155/2014/309129] [PMID: 25025046]
[4]
Isaac CP, Sivakumar A, Kumar CRP. Lead levels in breast milk, blood plasma and intelligence quotient: A health hazard for women and infants. Bull Environ Contam Toxicol 2012; 88(2): 145-9.
[http://dx.doi.org/10.1007/s00128-011-0475-9] [PMID: 22105937]
[5]
Ettinger AS, Téllez-Rojo MM, Amarasiriwardena C, et al. Effect of breast milk lead on infant blood lead levels at 1 month of age. Environ Health Perspect 2004; 112(14): 1381-5.
[http://dx.doi.org/10.1289/ehp.6616] [PMID: 15471729]
[6]
Yang Y, Ma Y, Ni L, et al. Lead exposure through gestation-only caused long-term learning/memory deficits in young adult offspring. Exp Neurol 2003; 184(1): 489-95.
[http://dx.doi.org/10.1016/S0014-4886(03)00272-3] [PMID: 14637118]
[7]
Kuhlmann AC, McGlothan JL, Guilarte TR. Developmental lead exposure causes spatial learning deficits in adult rats. Neurosci Lett 1997; 233(2-3): 101-4.
[http://dx.doi.org/10.1016/S0304-3940(97)00633-2] [PMID: 9350842]
[8]
Khan DA, Qayyum S, Saleem S, Khan FA. Lead-induced oxidative stress adversely affects health of the occupational workers. Toxicol Ind Health 2008; 24(9): 611-8.
[http://dx.doi.org/10.1177/0748233708098127] [PMID: 19106128]
[9]
Sanders T, Liu Y, Buchner V, Tchounwou PB. Neurotoxic effects and biomarkers of lead exposure: A review. Rev Environ Health 2009; 24(1): 15-45.
[http://dx.doi.org/10.1515/REVEH.2009.24.1.15] [PMID: 19476290]
[10]
Exposure to environmental lead can cause Alzheimer’s disease: Study. Available from: https://www.livemint.com/science/health/exposure-to-environmental-lead-can-cause-alzheimer-s-disease-study-11578928379224.html (Accessed on 30 May 2021).
[11]
Hossain S, Bhowmick S, Jahan S, et al. Maternal lead exposure decreases the levels of brain development and cognition-related proteins with concomitant upsurges of oxidative stress, inflammatory response and apoptosis in the offspring rats. Neurotoxicol 2016; 56: 150-8.
[http://dx.doi.org/10.1016/j.neuro.2016.07.013] [PMID: 27492863]
[12]
Oprea TI, Bauman JE, Bologa CG, et al. Drug repurposing from an academic perspective. Drug Discov Today Ther Strateg 2011; 8(3-4): 61-9.
[http://dx.doi.org/10.1016/j.ddstr.2011.10.002] [PMID: 22368688]
[13]
Gibbs JE, Walker MC, Cock HR. Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia 2006; 47(3): 469-78.
[http://dx.doi.org/10.1111/j.1528-1167.2006.00454.x] [PMID: 16529608]
[14]
Lyseng-Williamson KA. Levetiracetam: A review of its use in epilepsy. Drugs 2011; 71(4): 489-514.
[PMID: 21395360]
[15]
Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002; 136(5): 659-72.
[http://dx.doi.org/10.1038/sj.bjp.0704766] [PMID: 12086975]
[16]
Oliveira AA, Almeida JPC, Freitas RM, et al. Effects of levetiracetam in lipid peroxidation level, nitrite-nitrate formation and antioxidant enzymatic activity in mice brain after pilocarpine-induced seizures. Cell Mol Neurobiol 2007; 27(3): 395-406.
[http://dx.doi.org/10.1007/s10571-006-9132-y] [PMID: 17205390]
[17]
Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu DG. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 2001; 10(4): 279-86.
[http://dx.doi.org/10.1053/seiz.2000.0504] [PMID: 11466024]
[18]
Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 2008; 22(8): 999-1012.
[http://dx.doi.org/10.1002/ptr.2399] [PMID: 18618524]
[19]
Kulkarni SK, Dhir A. Berberine: A plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res 2010; 24(3): 317-24.
[http://dx.doi.org/10.1002/ptr.2968] [PMID: 19998323]
[20]
Mahmoud YI, Sayed SS. Effects of L-cysteine on lead acetate induced neurotoxicity in albino mice. Biotech Histochem 2016; 91(5): 327-32.
[http://dx.doi.org/10.3109/10520295.2016.1164897] [PMID: 27045382]
[21]
Amedu NO, Omotoso GO. Lead acetate-induced neurodegenerative changes in the dorsolateral prefrontal cortex of mice: The role of vitexin. Env Anal Health Toxicol 2020; 35(1): e2020001.
[http://dx.doi.org/10.5620/eaht.e2020001]
[22]
Puchchakayala G, Sravanthi A. Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress. J Alzheimers Dis 2012; 74: 857-62.
[23]
Pascal S, Zhu L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. National Academy of Sciences. PNAS Early Edition 2012; 109(42): 1-9.
[24]
Liang KW, Ting CT, Yin SC, et al. Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury. Biochem Pharmacol 2006; 71(6): 806-17.
[http://dx.doi.org/10.1016/j.bcp.2005.12.028] [PMID: 16448624]
[25]
Mizoguchi H, Takuma K, Fukuzaki E, et al. Matrix metalloprotease-9 inhibition improves amyloid beta-mediated cognitive impairment and neurotoxicity in mice. J Pharmacol Exp Ther 2009; 331(1): 14-22.
[http://dx.doi.org/10.1124/jpet.109.154724] [PMID: 19587312]
[26]
Wall PM, Messier C. Infralimbic kappa opioid and muscarinic M1 receptor interactions in the concurrent modulation of anxiety and memory. Psychopharmacology (Berl) 2002; 160(3): 233-44.
[http://dx.doi.org/10.1007/s00213-001-0979-9] [PMID: 11889492]
[27]
Butterfield D, Castegna A, Pocernich C, Drake J, Scapagnini G, Calabrese V. Nutritional approaches to combat oxidative stress in Alzheimer’s disease. J Nutr Biochem 2002; 13(8): 444-61.
[http://dx.doi.org/10.1016/S0955-2863(02)00205-X] [PMID: 12165357]
[28]
Casas M, Prat G, Robledo P, Barbanoj M, Kulisevsky J, Jané F. Scopolamine prevents tolerance to the effects of caffeine on rotational behavior in 6-hydroxydopamine-denervated rats. Eur J Pharmacol 1999; 366(1): 1-11.
[http://dx.doi.org/10.1016/S0014-2999(98)00911-X] [PMID: 10064145]
[29]
Cheng G, Whitehead SN, Hachinski V, Cechetto DF. Effects of pyrrolidine dithiocarbamate on beta-amyloid (25-35)-induced inflammatory responses and memory deficits in the rat. Neurobiol Dis 2006; 23(1): 140-51.
[http://dx.doi.org/10.1016/j.nbd.2006.02.008] [PMID: 16624564]
[30]
Chen D, Wu CF, Shi B, Xu YM. Tamoxifen and toremifene impair retrieval, but not acquisition, of spatial information processing in mice. Pharmacol Biochem Behav 2002; 72(1-2): 417-21.
[http://dx.doi.org/10.1016/S0091-3057(01)00782-1] [PMID: 11900814]
[31]
Saxena G, Singh SP, Pal R, Singh S, Pratap R, Nath C. Gugulipid, an extract of Commiphora whighitii with lipid-lowering properties, has protective effects against streptozotocin-induced memory deficits in mice. Pharmacol Biochem Behav 2007; 86(4): 797-805.
[http://dx.doi.org/10.1016/j.pbb.2007.03.010] [PMID: 17477963]
[32]
Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-95.
[http://dx.doi.org/10.1016/0006-2952(61)90145-9] [PMID: 13726518]
[33]
Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978; 86(1): 271-8.
[http://dx.doi.org/10.1016/0003-2697(78)90342-1] [PMID: 655387]
[34]
Jollow DJ, Mitchell JR, Zampaglione N, Gillette JR. Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology 1974; 11(3): 151-69.
[http://dx.doi.org/10.1159/000136485] [PMID: 4831804]
[35]
Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2006; 9(1): 101-24.
[http://dx.doi.org/10.1017/S1461145705005833] [PMID: 16083515]
[36]
Giacobini E. Cholinesterase inhibitors: New roles and therapeutic alternatives. Pharmacol Res 2004; 50(4): 433-40.
[http://dx.doi.org/10.1016/j.phrs.2003.11.017] [PMID: 15304240]
[37]
Abdel Moneim AE, Moneim A. Flaxseed oil as a neuroprotective agent on lead acetate-induced monoamineric alterations and neurotoxicity in rats. Biol Trace Elem Res 2012; 148(3): 363-70.
[http://dx.doi.org/10.1007/s12011-012-9370-4] [PMID: 22395955]
[38]
Bokara KK, Blaylock I, Denise SB, Bettaiya R, Rajanna S, Yallapragada PR. Influence of lead acetate on glutathione and its related enzymes in different regions of rat brain. J Appl Toxicol 2009; 29(5): 452-8.
[http://dx.doi.org/10.1002/jat.1423] [PMID: 19263481]
[39]
Yeğen B, Dedeoğlu A, Aykaç I, Oktay S, Yalçin AS. Effect of cold-restraint stress on glutathione and lipid peroxide levels in the liver and glandular stomach of rats. Pharmacol Res 1990; 22(1): 45-8.
[http://dx.doi.org/10.1016/1043-6618(90)90742-V] [PMID: 2330338]
[40]
Singh A. Lead-induced oxidative stress and role of antioxidants in its management. Asian J Biol Sci 2002; 9: 113-7.
[41]
Barkur RR, Bairy LK. Histological study on hippocampus, amygdala and cerebellum following low lead exposure during prenatal and postnatal brain development in rats. Toxicol Ind Health 2016; 32(6): 1052-63.
[http://dx.doi.org/10.1177/0748233714545624] [PMID: 25147304]

Rights & Permissions Print Cite
Article Metrics
32
2
© 2024 Bentham Science Publishers | Privacy Policy